Leqvio Injection, Solution
Product Images NDC 0078-1000

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Leqvio (NDC 0078-1000). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Molecular Formula Of Inclisiran Sodium (Leqvio 01)

Molecular Formula Of Inclisiran Sodium (Leqvio 01)
FDA Label Image

Figure 1: Mean Percent Change From Baseline In Ldl-c Over 18 Months In Patients With Ascvd On Maximally Tolerated Statin Therapy (study 1) (Leqvio 02)

Figure 1: Mean Percent Change From Baseline In Ldl-c Over 18 Months In Patients With Ascvd On Maximally Tolerated Statin Therapy (study 1) (Leqvio 02)
This appears to be a table showing the percent change from baseline in patients taking either "incisarian" or a placebo for the "ORION-10" study. The study appears to involve 70-75 patients taking the placebo and 61-78 patients taking the incisiran over a period of several months.*
FDA Label Image

Figure 2: Mean Percent Change From Baseline In Ldl-c Over 18 Months In Patients With Ascvd On Maximally Tolerated Statin Therapy (study 2) (Leqvio 03)

Figure 2: Mean Percent Change From Baseline In Ldl-c Over 18 Months In Patients With Ascvd On Maximally Tolerated Statin Therapy (study 2) (Leqvio 03)
This appears to be a chart or table showing the levels of DL cholesterol in a group of patients who were either given a placebo or the drug "Inciiran." The number of patients in each group is listed, along with their cholesterol levels. However, without more context it is difficult to provide a more detailed description or interpretation of the data.*
FDA Label Image

Figure 3: Mean Percent Change From Baseline In Ldl-c Over 18 Months In Patients With Hefh On Maximally Tolerated Statin Therapy (study 3) (Leqvio 04)

Figure 3: Mean Percent Change From Baseline In Ldl-c Over 18 Months In Patients With Hefh On Maximally Tolerated Statin Therapy (study 3) (Leqvio 04)
The text describes the change in LDL cholesterol levels in patients receiving a drug called inclisiran compared to a placebo over a period of time. The data is presented in a table showing the number of patients in each group.*
FDA Label Image

Principal Display Panel Leqvio® (inclisiran) Injection Contains One Single-dose Prefilled Syringe For Subcutaneous Use For Administration By A Healthcare Professional Only 284 mg/1.5 mL (189 mg/ml) Ndc 0078-1000-60 Sterile Solution Rx Only Novartis (Leqvio 05)

Principal Display Panel Leqvio® (inclisiran) Injection Contains One Single-dose Prefilled Syringe For Subcutaneous Use For Administration By A Healthcare Professional Only 284 mg/1.5 mL (189 mg/ml) Ndc 0078-1000-60 Sterile Solution Rx Only Novartis (Leqvio 05)
LEQVIO® (inclisiran) injection is used for subcutaneous administration and comes in a single-dose pre-filled syringe of 1.5 mL containing 284mg inclisiran. It may contain sodium hydroxide and/or phosphoric acid for pH adjustment. The recommended dosage should be referred to in the prescribing information. The storage guidelines are between 2°C and 8°C (36°F and 46°F), with excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. It should be discarded after single use. The product contains no preservatives or natural rubber latex. For further information, visit www.LEQVIO.com or call 1-858-669-6652. Note: quality not high.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.